Ribavirin plasma concentration measurements in patients with hepatitis C: Early ribavirin concentrations predict steady-state concentrations

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 40-44

  Slavenburg, Serena ^a   Huntjens Fleuren, Hanneke W H A ^b   Dofferhoff, Ton S M ^b   Richter, Clemens ^c   Koopmans, Peter P ^a   Verwey Van Wissen, Corrien P W G M ^a,d   Drenth, Joost P H ^a   Burger, David M ^a,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

^d Nijmegen Institute of Infection Inflammation and Immunology (N4i)   (Netherlands)

Author keywords

hepatitis C; plasma concentration; ribavirin; therapeutic drug monitoring

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 78751646764     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318205f892     Document Type: Article

References (22)

1. Ghany MC, Strader DB, Thomas DL, et al; American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
2. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
4. McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
5. Manns M, Muir A, Adda N, et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE-3 study. In: Program and abstracts of the 44th Annual Meeting of the European Association for the Study of Liver April Denmark, Copenhagen 2009. Abstract 1044, p 379.
6. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 Final results: SVR 24 from a phase 2 study of boceprevir plus peginterferonalfa-2b/ribavirin in treatment-na?̈ve subjects with genotype-1 chronic hepatitis C. In: Program and abstract of the 44th Annual Meeting of the European Association for the Study of Liver Denmark, Copenhagen 2009. Abstract 4, p 4.
7. Lindahl K, Stahle L, Bruchfeld A, et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005;41:275-279.
8. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007;46:371-379.
9. Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-totreat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008;48:1033-1043.
10. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999;9: 17-24.
11. Tsubota A, Hirose Y, Izumi N, et al. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol. 2003;55:360-367. (Pubitemid 36535366)
12. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555-565.
13. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008;47:1453-1461.
14. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology. 2005;48:138-144.
15. Maynard M, Pradat P, Gagnieu MC, et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther. 2008;13: 607-611.
16. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother. 2008;61: 919-924.
17. Rendón AL, Núñez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2005;39:401-405.
18. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol. 2008;80:1523-1529.
19. Morello J, Rodŕguez-Novoa S, Jiménez-Nácher I, et al. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62: 1174-1180.
20. de Bruijne J, Buster EH, Gelderblom HC, et al; Netherlands Association of Gastroenterologists and Hepatologists. Treatment of chronic hepatitis C virus infection-Dutch national guidelines. Neth J Med. 2008;66: 311-322.
21. D' Avolio A, Ibanez A, Sciandra M, et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835:127-130.
22. Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict HCV relapse in HIV/HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother. 2010;54:1647-1649.